G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
GTHXG1 Therapeutics(GTHX) Newsfilter·2024-05-01 18:30
  • Achieved 14.1MillioninNetRevenuefromSalesofCOSELA®(trilaciclib)forFirstQuarter2024−−Reaffirmed2024NetCOSELARevenueGuidanceof14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of 60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) Will Be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - - Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in 1L Metastatic Triple Neg ...